银屑病与代谢综合征:对银屑病管理和治疗的意义
银屑病是一种与多种共病相关的慢性系统性炎症性疾病,代谢综合征是其最常见的共病,也是心血管疾病的风险因素。本文综述银屑病与代谢综合征共享的炎症机制,并讨论银屑病治疗降低心血管风险的最新临床证据。
要点
- 代谢综合征是银屑病最常见的共病,也是心血管疾病的风险因素。
- IL-23/Th-17免疫信号通路失调是银屑病与代谢综合征共有的核心机制。
- 近期影像研究显示皮损改善与血管炎症改善相关,生物制剂获益可能超越皮肤。
核心结论
- 银屑病与代谢综合征的确切因果关系尚未完全确立,但两者似乎涉及重叠的遗传易感性和炎症通路。
- IL-23/Th-17免疫信号通路失调是两者共有的核心机制,可能促进代谢和心血管疾病的易感性。
- 近期影像研究显示皮损改善与血管炎症改善相关,生物制剂的获益可能超越皮肤并有助于预防心血管疾病。
研究设计与样本
- 综述,总结银屑病与代谢综合征共享的炎症机制及银屑病治疗降低心血管风险的最新临床证据。
主要发现
- 代谢综合征是银屑病最常见的共病,也是心血管疾病的风险因素,后者是银屑病患者的主要死因之一。
- 银屑病与代谢综合征的确切因果关系尚未完全确立,但似乎涉及重叠的遗传易感性和炎症通路。
- IL-23/Th-17免疫信号通路失调是两者共有的核心机制,可能促进代谢和心血管疾病的易感性。
- 近期影像研究显示皮损改善与血管炎症改善相关,生物制剂的获益可能超越皮肤并有助于预防心血管疾病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psoriasis is a chronic systemic inflammatory disorder associated with several comorbidities in addition to the characteristic skin lesions. Metabolic syndrome (MetS) is the most frequent comorbidity in psoriasis and a risk factor for cardiovascular disease, a major cause of death among patients with psoriasis. Although the exact causal relationship between these two disorders is not fully established, the underlying pathophysiology linking psoriasis and MetS seems to involve overlapping genetic predispositions and inflammatory pathways. Dysregulation of the IL-23/Th-17 immune signalling pathway is central to both pathologies and may be key to promoting susceptibility to metabolic and cardiovascular diseases in individuals with and without psoriasis. Thus, biological treatments for psoriasis that interrupt these signals could both reduce the psoriatic inflammatory burden and also lessen the risk of developing atherosclerosis and cardiometabolic diseases. In support of this hypothesis, improvement of skin lesions was associated with improvement in vascular inflammation in recent imaging studies, demonstrating that the beneficial effect of biological agents goes beyond the skin and could help to prevent cardiovascular disease. This review will summarize current knowledge on underlying inflammatory mechanisms shared between psoriasis and MetS and discuss the most recent clinical evidence for the potential for psoriasis treatment to reduce cardiovascular risk.
引用
- Wu JJ, Kavanaugh A, Lebwohl MG, et al. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022. PMID: 35238067. doi:10.1111/jdv.18044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。